Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
ALGS compared with SENS: revenue, margins and what each company keeps, and the suppliers and customers both name
ALGS
Aligos Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
SENS
Senseonics Holdings, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
ALGS
Aligos Therapeutics, Inc.
vs
SENS
Senseonics Holdings, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
ALGS, solid
SENS, dashed
Supply-chain overlap
Revenue flow
ALGS: latest quarter is a loss; flow not drawable. SENS: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only ALGS
15
MRK
Merck Sharp & Dohme
customer
ADCT
ADC Therapeutics (ADCT)
customer
—
Emory University
unlisted
supplier
—
Rega Institute at Katholieke Universiteit Leuven (KU Leuven)
unlisted
supplier
11 more · ALGS chain
›
Shared
0
No shared counterparties.
Only SENS
3
—
BSI
unlisted
supplier
—
NPG
unlisted
supplier
—
Ascensia Diabetes Care Holdings AG ("Ascensia")
unlisted
customer
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
ALGS
Aligos Therapeutics, Inc.
Change
4.76
· pre 4.98
· delayed
Mkt cap
$59.3M
Revenue
$28M
Q2 FY26
Revenue
$2M
FY25
SENS
Senseonics Holdings, Inc.
Change
9.03
· pre 9.03
· delayed
Pre-market
Nov 4 '26
delayed
Mkt cap
$468.5M
Revenue
$14M
Q2 FY26
Revenue
$35M
FY25
vs
Compare
Pre-market
Nov 4 '26
delayed
ALGS
Aligos Therapeutics, Inc.
vs
SENS
Senseonics Holdings, Inc.
4.76
pre 4.98
delayed
Price
9.03
pre 9.03
delayed
$59.3M
Mkt cap
$468.5M
Q2 FY26
$28M
Revenue
$14M
Q2 FY26
FY25
$2M
Revenue
$35M
FY25
Change
Change
ALGS
4.76
vs
SENS
9.03
Pre-market
Nov 4 '26
delayed